Competitive swimmers hyperventilate

A discussion in my A&P 2 class on this article below. can you assist ?  if using reference please provide

Some competitive swimmers hyperventilate before a race, thinking they can “load up extra oxygen” and hold their breaths longer underwater. While they can indeed hold their breaths longer, it is not for the reason they think. Furthermore, some have lost consciousness and drowned because of this practice. What is wrong with this thinking, and what accounts for the loss of consciousness?

The following article, to some degree, provide counter view of this problem, and hopefully will helps you with your thinking.

Rare diseases and drug discovery don’t usually make for Hollywood blockbusters. But a film about a genetic affliction that strikes fewer than 10,000 people worldwide hits movie screens, and it has some serious star power behind it. Harrison Ford and Brendan Fraser head up the cast of Extraordinary Measures, a new movie that may lift Pompe disease from the shadows of obscurity into the spotlight, as the focal point of an inspirational story of paternal love and scientific innovation.

 

A screen shot from the movie. Note The Scientist‘s poking cameo
appearance next to the computer(black arrow).
Image: YouTube trailer (screen shot)

“The movie is a great exposure for a rare genetic disease,” said Duke University School of Medicine’s linkurl:Priya Kishnani,;http://www.dukehealth.org/physicians/priya_kishnani who studies Pompe and participated in much of the research that led to the first and only approved treatment for the disease — a quest that forms the central plot of the film. “I would have never thought in my lifetime, a disease that I’m so passionate about would make it into mainstream Hollywood cinema.”Extraordinary Measures tells the tale of businessman linkurl:John Crowley;http://www.crowleyfamily5.com/ (played by Fraser) who makes it his mission to promote the development of an enzyme therapy to treat his two youngest children, who are sick with Pompe. Teaming up with University of Nebraska researcher Robert Stonehill (Ford), Crowley starts a small biotech company called Priozyme dedicated to his purpose. (In reality, the researcher who helped Crowley was William Canfield of the University of the Oklahoma Health Sciences Center, and the company Crowley launched was called Novazyme.) Pompe disease is a genetic lysosomal storage disorder. Any of the nearly 300 mutations in the lysosomal enzyme acid ?-glucosidase (GAA) gene that affect its function can result in either infantile- or late-onset accumulation of glycogen in muscle tissues. Pompe destroys skeletal muscle, impairing motor skills and usually relegating patients to wheelchairs. The disease also compromises lung and heart function, with most Pompe patients ending up on ventilators with inflamed and failing hearts. Infants with Pompe disease typically survive less than one year, while late onset patients can suffer only mild symptoms for years before experiencing an abrupt decline. As the movie depicts, Novazyme was eventually bought out by linkurl:Genzyme;http://www.genzyme.com/ (Zymagen in the movie), a larger biotech company that was also developing a Pompe therapy and had purchased two others. Now with four different enzymes to choose from, Genzyme ran what they call the “Mother of All Experiments,” pitting the four candidates against one another in blinded biochemical analyses and mouse model tests to see which held the most promise. Once the results were in, a group that included Canfield, as well as Genzyme’s vice president, Robert Mattaliano, selected the winner, revealing the drug’s identity by decoding the color-schemed key. There was “this great collage of [people with] the desire to come up with something would serve the needs of this patient population,” Mattaliano told The Scientist. “It was quite a team effort.” The winner — a recombinant human form of the GAA enzyme (rhGAA) produced in a Chinese hamster ovary cell line — was the subject of three clinical trials: one for infantile-onset Pompe patients, one for patients aged 3 months to 3.5 years, and one for the two Crowley children, who were able to receive treatment at a local New Jersey hospital near their home after their father left his position at Genzyme. The trials showed significantly decreased mortality, and patients were able to survive longer without the aid of a ventilator, and some even demonstrated increased motor function. In 2006, the treatment, an intravenous enzyme replacement therapy dubbed Myozyme, became the first and only approved treatment for Pompe disease. While Crowley’s children are still on respirators, they are responding well to their Myozyme treatments, which they continue to this day. Extraordinary Measures tells this story with remarkable accuracy (albeit with some minor Hollywood name changes and plot tweaks), and shines a light on Pompe that rarely touches most rare diseases. But somewhere in the recounting of this emotionally driven tale, the viewer, at least the scientifically-inclined one, is alienated from the realities of the disease. The sick children, while on ventilators and in wheelchairs, speak with ease — an overly optimistic picture of Pompe patients, who often have much more difficulty communicating. The movie also typecasts theoretical endeavors as idealistic and even useless, dismissing a branch of research that provides the basis of most bench and clinical work. The film does a better job of representing the hard-to-swallow fiscal issues of drug development. “The movie emphasizes how these things can be monetized,” University of Florida pediatric cardiologist linkurl:Barry Byrne;http://www.mgm.ufl.edu/faculty/bbyrne.htm told The Scientist. “Everything cannot be done at the research level,” aIDed Byrne, who was involved in the clinical trials of Myozyme. “Without investments from a company like Genzyme to bring these products to patients there would be no benefit to patients in the long run.” Since the development of Myozyme, research on treatments for Pompe disease has continued and expanded. Most recently, Byrne opened a linkurl:clinical trial;http://clinicaltrials.gov/ct2/show/NCT00976352?& to test a gene therapy supplement to the enzyme replacement therapy. A handful of biotechs are also developing new Pompe drugs, including Genzyme which is currently working on their second generation compound. “It’s really striking that for such a small community of patients that there is so much interest,” Byrne said. “And [hopefully it will be] catalyzed by the public interest in the film.”

"Is this question part of your assignment? We can help"

ORDER NOW